Agios Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Agios Pharmaceuticals, Inc.

Dec-08	Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia AGIO GlobeNewswire
Nov-19	Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease AGIO GlobeNewswire
Nov-03	Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition AGIO GlobeNewswire
Oct-30	Agios Reports Third Quarter 2025 Financial Results and Provides Business Update AGIO GlobeNewswire
Oct-17	Agios' PYRUKYND (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia AGIO GlobeNewswire
Oct-16	Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET AGIO GlobeNewswire
Sep-04	Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND (mitapivat) in Thalassemia AGIO GlobeNewswire
Aug-04	Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia AGIO GlobeNewswire
Jul-31	Agios Reports Second Quarter 2025 Financial Results and Provides Business Update AGIO GlobeNewswire
Jul-14	Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET AGIO GlobeNewswire
Jul-08	Agios Appoints Dr. Jay Backstrom to Board of Directors AGIO GlobeNewswire
May-28	Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 AGIO GlobeNewswire
May-14	Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress AGIO GlobeNewswire
May-09	Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 AGIO GlobeNewswire
May-02	Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 AGIO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.